{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:34:42Z","timestamp":1793082882052,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:00:00Z","timestamp":1701475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:00:00Z","timestamp":1701475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00228-023-03599-w","type":"journal-article","created":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T02:02:12Z","timestamp":1701482532000},"page":"239-248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetics of oral spironolactone in infants up to 2\u00a0years of age"],"prefix":"10.1007","volume":"80","author":[{"given":"Jana","family":"Lass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Leroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenne-Triin","family":"K\u00f5rgvee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heili","family":"Varendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Kipper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalev","family":"Takkis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Aro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuuli","family":"Metsvaht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kersti","family":"Oselin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiie","family":"Soeorg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"van den Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irja","family":"Lutsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,2]]},"reference":[{"issue":"6","key":"3599_CR1","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s11936-009-0045-1","volume":"11","author":"EM Volz","year":"2009","unstructured":"Volz EM, Michael FG (2009) How to use diuretics in heart failure. Curr Treat Options Cardiovasc Med 11(6):426\u2013432","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"5","key":"3599_CR2","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1517\/13543784.10.5.943","volume":"10","author":"SA Doggrell","year":"2001","unstructured":"Doggrell SA, Brown L (2001) The spironolactone renaissance. Expert Opin Investig Drugs 10(5):943\u2013954","journal-title":"Expert Opin Investig Drugs"},{"issue":"8\u20139","key":"3599_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/j.1552-4604.1982.tb02694.x","volume":"22","author":"GT McInnes","year":"1982","unstructured":"McInnes GT, Asbury MJ, Ramsay LE, Shelton JR, Harrison IR (1982) Effect of micronization on the bioavailability and pharmacologic activity of spironolactone. J Clin Pharmacol 22(8\u20139):410\u2013417","journal-title":"J Clin Pharmacol"},{"key":"3599_CR4","doi-asserted-by":"crossref","unstructured":"Nolan Jr PE (2004) Integrating traditional and emerging treatment options in heart failure.\u00a0Am J Health Syst Pharm 61(suppl_2):S14\u201322","DOI":"10.1093\/ajhp\/61.suppl_2.S14"},{"issue":"5","key":"3599_CR5","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/j.1365-2125.2012.04257.x","volume":"74","author":"M Suyagh","year":"2012","unstructured":"Suyagh M, Hawwa AF, Collier PS, Millership JS, Kole P, Millar M, Shields MD, Halliday HL, McElnay JC (2012) Population pharmacokinetic model of canrenone after intravenous administration of potassium canrenoate to paediatric patients. Br J Clin Pharmacol 74(5):864\u2013872","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"3599_CR6","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/j.1552-4604.1989.tb03339.x","volume":"29","author":"P Gardiner","year":"1989","unstructured":"Gardiner P, Schrode K, Quinlan D, Martin BK, Boreham DR, Rogers MS, Stubbs K, Smith M, Karim A (1989) Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol 29(4):342\u2013347","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"3599_CR7","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology\u2014drug disposition, action, and therapy in infants and children. N Engl J Med 349(12):1157\u20131167","journal-title":"N Engl J Med"},{"issue":"5","key":"3599_CR8","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1345\/aph.1E618","volume":"39","author":"ML Buck","year":"2005","unstructured":"Buck ML (2005) Clinical experience with spironolactone in pediatrics. Ann Pharmacother 39(5):823\u2013828","journal-title":"Ann Pharmacother"},{"issue":"12","key":"3599_CR9","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1007\/s00216-017-0255-4","volume":"409","author":"K Takkis","year":"2017","unstructured":"Takkis K, Aro R, K\u00f5rgvee L-T, Varendi H, Lass J, Herodes K et al (2017) Signal enhancement in the HPLC-ESI-MS\/MS analysis of spironolactone and its metabolites using HFIP and NH4F as eluent additives. Anal Bioanal Chem 409(12):3145\u20133151","journal-title":"Anal Bioanal Chem"},{"issue":"5","key":"3599_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28(5):481","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"3599_CR11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/clpt.1985.206","volume":"38","author":"HW Overdiek","year":"1985","unstructured":"Overdiek HW, Hermens WA, Merkus FW (1985) New insights into the pharmacokinetics of spironolactone. Clin Pharmacol Ther 38(4):469\u2013474","journal-title":"Clin Pharmacol Ther"},{"key":"3599_CR12","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s40262-017-0544-2","volume":"56","author":"S de Hoogd","year":"2017","unstructured":"de Hoogd S, V\u00e4litalo PA, Dahan A, van Kralingen S, Coughtrie MM, van Dongen EP, van Ramshorst B, Knibbe CA (2017) Influence of morbid obesity on the pharmacokinetics of morphine, morphine-3-glucuronide, and morphine-6-glucuronide. Clin Pharmacokinet 56:1577\u20131587","journal-title":"Clin Pharmacokinet"},{"key":"3599_CR13","unstructured":"Spironolactone product monograph available at: https:\/\/www.medicines.org.uk\/emc\/product\/1619\/smpc"},{"key":"3599_CR14","unstructured":"Spironolactone product monograph available at: https:\/\/www.medsafe.govt.nz\/profs\/datasheet\/s\/Spiractintab.pdf"},{"issue":"5","key":"3599_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2165\/00003088-199630050-00001","volume":"30","author":"NH Holford","year":"1996","unstructured":"Holford NH (1996) A size standard for pharmacokinetics. Clin Pharmacokinet 30(5):329\u2013332","journal-title":"Clin Pharmacokinet"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03599-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03599-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03599-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T05:02:39Z","timestamp":1707454959000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03599-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,2]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["3599"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03599-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3095864\/v1","asserted-by":"object"}]},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,2]]},"assertion":[{"value":"22 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved of the Research Ethics Committee of the University of Tartu (Approval No 249[M-12).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Individuals have been given consent to participate in a study and consent having their data published in a journal article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}